Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.

Dr. Barbara L. McAneny’s withdrawal from the EOM program underscores the critical need for healthcare models to align with the realities of patient care, especially in community settings where the impact of social determinants is most pronounced.

Radiation oncology is facing a pivotal moment with a decline in residency applicants and unmatched positions, signaling a need for the field to reevaluate its approach to education, training, and diversity to ensure a sustainable future.

In a recent randomized trial comparing radical and simple hysterectomy in patients with low-risk cervical cancer, findings demonstrated that simple hysterectomy was not inferior in preventing pelvic recurrence at 3 years and offered a significant reduction in postoperative urinary complications.

The REVIVE trial elucidates rusfertide’s capacity to maintain hematocrit levels below 45% during its 28-week study period, underscoring its potential as a transformative agent in the treatment of polycythemia vera. This efficacy, coupled with a favorable safety profile, marks a significant advancement in therapeutic options for this chronic condition.

Better Therapeutics’ digital therapeutic app has been recognized with FDA breakthrough device status, showcasing its potential in significantly reducing liver fat in patients with advanced liver disease through cognitive behavioral therapy.